| Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer KC Patra, Q Wang, PT Bhaskar, L Miller, Z Wang, W Wheaton, N Chandel, ... Cancer cell 24 (2), 213-228, 2013 | 883 | 2013 |
| SUMO-specific protease 2 is essential for suppression of polycomb group protein-mediated gene silencing during embryonic development X Kang, Y Qi, Y Zuo, Q Wang, Y Zou, RJ Schwartz, J Cheng, ETH Yeh Molecular cell 38 (2), 191-201, 2010 | 236 | 2010 |
| SUMO-specific protease 1 promotes prostate cancer progression and metastasis Q Wang, N Xia, T Li, Y Xu, Y Zou, Y Zuo, Q Fan, T Bawa-Khalfe, ETH Yeh, ... Oncogene 32 (19), 2493-2498, 2013 | 155 | 2013 |
| Akt as a target for cancer therapy: more is not always better (lessons from studies in mice) Q Wang, X Chen, N Hay British journal of cancer 117 (2), 159-163, 2017 | 143 | 2017 |
| Spontaneous hepatocellular carcinoma after the combined deletion of Akt isoforms Q Wang, WN Yu, X Chen, X Peng, SM Jeon, MJ Birnbaum, G Guzman, ... Cancer cell 29 (4), 523-535, 2016 | 116 | 2016 |
| SUMOylation controls the binding of hexokinase 2 to mitochondria and protects against prostate cancer tumorigenesis X Shangguan, J He, Z Ma, W Zhang, Y Ji, K Shen, Z Yue, W Li, Z Xin, ... Nature communications 12 (1), 1812, 2021 | 95 | 2021 |
| Glucose limitation activates AMPK coupled SENP1-Sirt3 signalling in mitochondria for T cell memory development J He, X Shangguan, W Zhou, Y Cao, Q Zheng, J Tu, G Hu, Z Liang, ... Nature communications 12 (1), 4371, 2021 | 89 | 2021 |
| SENP1 deficiency promotes ER stress-induced apoptosis by increasing XBP1 SUMOylation Z Jiang, Q Fan, Z Zhang, Y Zou, R Cai, Q Wang, Y Zuo, J Cheng Cell cycle 11 (6), 1118-1122, 2012 | 49 | 2012 |
| The Evolving Role of 18F-FDG PET/CT in Diagnosis and Prognosis Prediction in Progressive Prostate Cancer K Shen, B Liu, X Zhou, Y Ji, L Chen, Q Wang, W Xue Frontiers in oncology 11, 683793, 2021 | 43 | 2021 |
| SENP1 regulates IFN-γ− STAT1 signaling through STAT3− SOCS3 negative feedback loop T Yu, Y Zuo, R Cai, X Huang, S Wu, C Zhang, YE Chin, D Li, Z Zhang, ... Journal of Molecular Cell Biology 9 (2), 144-153, 2017 | 39 | 2017 |
| HOXD13 suppresses prostate cancer metastasis and BMP4‐induced epithelial‐mesenchymal transition by inhibiting SMAD1 F Xu, X Shangguan, J Pan, Z Yue, K Shen, Y Ji, W Zhang, Y Zhu, J Sha, ... International journal of cancer 148 (12), 3060-3070, 2021 | 38 | 2021 |
| Comprehensive analysis of androgen receptor status in prostate cancer with neuroendocrine differentiation R Su, L Chen, Z Jiang, M Yu, W Zhang, Z Ma, Y Ji, K Shen, Z Xin, J Qi, ... Frontiers in Oncology 12, 955166, 2022 | 9 | 2022 |
| The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer Y Ji, W Zhang, K Shen, R Su, X Liu, Z Ma, B Liu, C Hu, Y Xue, Z Xin, ... Nature Communications 14 (1), 7794, 2023 | 4 | 2023 |
| Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6/STAT3 pathway Y Ji, B Liu, L Chen, A Li, K Shen, R Su, W Zhang, Y Zhu, Q Wang, W Xue Cellular Oncology 46 (5), 1445-1456, 2023 | 3 | 2023 |
| Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications Z Ma, X Cheng, T Yue, X Shangguan, Z Xin, W Zhang, J Pan, Q Wang, ... Cancer Medicine 10 (15), 5358-5374, 2021 | 3 | 2021 |
| 18F‐FDG PET/CT imaging in neuroendocrine prostate cancer: Relation to histopathology and prognosis K Shen, M Yu, Y Ji, X Zhou, B Liu, W Zhang, R Su, J Qi, Q Wang, W Xue The Prostate 83 (12), 1167-1175, 2023 | 2 | 2023 |
| High-throughput drug screening identifies fluoxetine as a potential therapeutic agent for neuroendocrine prostate cancer L Chen, Y Ji, A Li, B Liu, K Shen, R Su, Z Ma, W Zhang, Q Wang, Y Zhu, ... Frontiers in Oncology 13, 1085569, 2023 | 2 | 2023 |
| Prognostic value of [18F]FDG PET/CT in metastatic hormone-sensitive prostate cancer at initial diagnosis: a retrospective cohort study A Li, K Shen, Y Ji, W Zhang, B Liu, R Su, X Zhou, L Dong, Y Zhu, B Dong, ... Annals of Medicine 56 (1), 2411017, 2024 | 1 | 2024 |
Nissim Hay在 uic.edu 的电子邮件经过验证
Nissim Hay在 uic.edu 的电子邮件经过验证